Translational research in neurology: Dementia

Archives of Neurology

Volumn 69, Issue 8, 2012, Pages 969-977

  Honig, Lawrence S ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIARRHYTHMIC AGENT; AVAGACESTAT; BAPINEUZUMAB; BIOLOGICAL MARKER; CAD 106; CRENEZUMAB; DONEPEZIL; GALANTAMINE; GANTENERUMAB; MEMANTINE; PLACEBO; RIVASTIGMINE; SEMAGACESTAT; SOLANEZUMAB; TACRINE; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; VACCINE; VANUTIDE CRIDIFICAR;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN GENE; BLOOD ANALYSIS; BRAIN ATROPHY; BRAIN EDEMA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DEMENTIA; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE COURSE; DNA DETERMINATION; EARLY DIAGNOSIS; GENE; GENE MUTATION; GENETIC RISK; HUMAN; MENINGOENCEPHALITIS; MOLECULAR PATHOLOGY; NERVE CELL DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PATHOGENICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLATIONAL RESEARCH;

ALZHEIMER DISEASE; ANIMALS; DEMENTIA; HUMANS; NEUROLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84865618494     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.2883     Document Type: Review

References (51)

1. White L. Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study. J Alzheimers Dis. 2009;18(3):713-725.
2. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-208.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
4. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
5. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
6. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-1127.
7. Sabuncu MR, Desikan RS, Sepulcre J, et al Alzheimer's Disease Neuroimaging Initiative. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68(8):1040-1048.
8. Barnes J, Bartlett JW, van de Pol LA, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging. 2009;30(11):1711-1723.
9. Scher AI, Xu Y, Korf ES, et al. Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry. 2011;82(4):373-376.
10. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011;34(8):430-442.
11. Vemuri P, Wiste HJ, Weigand SD, et al Alzheimer's Disease Neuroimaging Initiative. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75(2):143-151.
12. Chen K, Ayutyanont N, Langbaum JB, et al Alzheimer's Disease Neuroimaging Initiative. Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011;56(1):52-60.
13. Womack KB, Diaz-Arrastia R, Aizenstein HJ, et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol. 2011;68(3):329-337.
14. Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68(2):232-240.
15. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
16. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363-372.
17. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512-519. (Pubitemid 43358072)
18. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
19. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359-1362. (Pubitemid 350073592)
20. Salloway S, Sperling R, Gilman S, et al Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab inmild to moderate Alzheimer disease. Neurology. 2009;73(24):2061-2070.
21. Petersen RC, Thomas RG, Grundman M, et al Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388. (Pubitemid 40958434)
22. Risner ME, Saunders AM, Altman JF, et al Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6(4):246-254. (Pubitemid 44137951)
23. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-385.
24. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241-249.
25. Reitz C, Cheng R, Rogaeva E, et al; Genetic and Environmental Risk in Alzheimer Disease 1 Consortium. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch Neurol. 2011;68(1):99-106.
26. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-441.
27. Jun G, Naj AC, Beecham GW, et al Alzheimer's Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473-1484.
28. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol. 2011;6:193-222.
29. Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24(6):542-549.
30. Borroni B, Pilotto A, Bianchi M, Gilberti N, Padovani A. Genetic contributors to frontotemporal lobar degeneration: beyond monogenic disease. Mini Rev Med Chem. 2011;11(11):988-1001.
31. Herrmann N, Li A, Lanctôt K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12(5):787-800.
32. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29-38.
33. Selkoe DJ. Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol. 2008;89:245-260.
34. Kukar TL, Ladd TB, Bann MA, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453(7197):925-929.
35. Green RC, Schneider LS, Amato DA, et al; Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557-2564.
36. Siemers ER, Friedrich S, Dean RA, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010;33(2):67-73.
37. Siemers E, Henley D, Sundell K, et al. Evaluating semagacestat, a gamma-secretase inhibitor, in a phase III trial. Alzheimer's & Dementia. 2011;7(4):S484-S485. doi:10.1016/j.jalz.2011.05.2355.
38. Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol Sci. 2004;25(2):92-97. (Pubitemid 38183395)
39. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173-177. (Pubitemid 29327547)
40. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1(1):24.
41. Gilman S, Koller M, Black RS, et al; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64(9):1553-1562. (Pubitemid 40617691)
42. Vellas B, Black R, Thal LJ, et al; AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009;6(2):144-151.
43. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372(9634):216-223. (Pubitemid 351978111)
44. Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human antiamyloid-beta active immunization on neurite morphology and tau pathology. Brain. 2010;133(pt 5):1312-1327.
45. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66(4):602-604. (Pubitemid 43739900)
46. Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30(11):1728-1736.
47. Lambracht-Washington D, Qu BX, Fu M, et al. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol. 2011;31(6):867-874.
48. Tuszynski MH. Nerve growth factor gene delivery: animal models to clinical trials. Dev Neurobiol. 2007;67(9):1204-1215. (Pubitemid 47229868)
49. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10(3):209-219.
50. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 2009;8(4):334-344.
51. Geschwind MD. Clinical trials for prion disease: difficult challenges, but hope for the future. Lancet Neurol. 2009;8(4):304-306.